(61e) Erythrocyte Anchored Systemic Immunotherapy: Metastasis Driven Cancer Immunotherapy for Local and Systemic Tumor Suppression
AIChE Annual Meeting
2020
2020 Virtual AIChE Annual Meeting
Food, Pharmaceutical & Bioengineering Division
Drug Delivery for Immune Modulation
Monday, November 16, 2020 - 9:00am to 9:15am
Immunomodulation in tumor microenvironments is a promising strategy to employ body’s own
immune system to treat tumors in patients with advanced cancer stages like metastasis. However,
achieving site-specific local immunomodulation post systemic administration has been a challenge.
Here we describe a new strategy, Erythrocyte Anchored Systemic Immunotherapy (EASI), that
enables local immuno-restoration in hard-to-reach cancer metastatic sites. Briefly, by engineering their
interactions with erythrocytes, ImmunoBait (chemokine nanoparticles) anchor onto erythrocytes, hitch
a ride and are precisely deposited in the vicinity of target metastatic sites. ImmunoBait gradually
releases chemokine, modulates the local microenviroment by restoring the chemokine gradient,
subsequently leading to a significant enhancement in the infiltration of effector immune cells. Our in
vivo results based on a spontaneous breast cancer lung metastasis model showed that EASY
remarkably inhibited the progression of lung metastasis and significantly extended the animal survival.
Moreover, the immune response induced by EASY significantly suppressed the growth of re-challenged
distant tumors. Our findings indicate that EASY is a potent strategy for immuno-modulation to
combat metastatic cancers.
immune system to treat tumors in patients with advanced cancer stages like metastasis. However,
achieving site-specific local immunomodulation post systemic administration has been a challenge.
Here we describe a new strategy, Erythrocyte Anchored Systemic Immunotherapy (EASI), that
enables local immuno-restoration in hard-to-reach cancer metastatic sites. Briefly, by engineering their
interactions with erythrocytes, ImmunoBait (chemokine nanoparticles) anchor onto erythrocytes, hitch
a ride and are precisely deposited in the vicinity of target metastatic sites. ImmunoBait gradually
releases chemokine, modulates the local microenviroment by restoring the chemokine gradient,
subsequently leading to a significant enhancement in the infiltration of effector immune cells. Our in
vivo results based on a spontaneous breast cancer lung metastasis model showed that EASY
remarkably inhibited the progression of lung metastasis and significantly extended the animal survival.
Moreover, the immune response induced by EASY significantly suppressed the growth of re-challenged
distant tumors. Our findings indicate that EASY is a potent strategy for immuno-modulation to
combat metastatic cancers.